- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
INCY — NASDAQ —
The stock's current RSI stands at 53.40, indicating a rebound from the 40 level, which reflects a favorable market sentiment.
The short length exponential moving average (5 EMA) is about to cross the long length exponential moving average (10 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our US swing trading stocks, Incyte Corporation stock price target will be USD 78.5 - SAR 80 in the next 14-15 trading sessions.
Incyte Corporation is a biopharmaceutical firm focused on discovering, developing, and commercializing therapies for haematology/oncology, inflammation, and autoimmunity globally. It offers JAKAFI for myelofibrosis, polycythemia vera, and acute graft-versus-host disease; MONJUVI/MINJUVI for diffuse large B-cell lymphoma; PEMAZYRE for tumors; ICLUSIG for chronic myeloid leukemia; ZYNYZ for Merkel cell carcinoma; and OPZELURA for atopic dermatitis. Its clinical pipeline includes retifanlimab in Phase 3 trials for anal canal and lung cancers, axatilimab for chronic GVHD in Phase 2, and several other investigational products. The company has partnerships with Novartis, Lilly, and others for development and commercialization. Formerly Incyte Genomics Inc, it rebranded to Incyte Corporation in March 2003.
INCY — NASDAQ —
The stock's current RSI stands at 53.40, indicating a rebound from the 40 level, which reflects a favorable market sentiment.
The short length exponential moving average (5 EMA) is about to cross the long length exponential moving average (10 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our US swing trading stocks, Incyte Corporation stock price target will be USD 78.5 - SAR 80 in the next 14-15 trading sessions.
